Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification

[1]  Jacob S. Young,et al.  The Surgical Management of Diffuse Gliomas: Current State of Neurosurgical Management and Future Directions. , 2023, Neuro-oncology.

[2]  Jong-Hee Chang,et al.  The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 1—Key Points of the Fifth Edition and Summary of Imaging Findings on Adult‐Type Diffuse Gliomas , 2023, Journal of magnetic resonance imaging : JMRI.

[3]  M. J. van den Bent,et al.  OS07.8.A Prognosis in IDH-mutant glioma: the role of extent-of-resection, age and tumor grade , 2022, Neuro-Oncology.

[4]  Sung Soo Ahn,et al.  Sex as a prognostic factor in adult-type diffuse gliomas: an integrated clinical and molecular analysis according to the 2021 WHO classification , 2022, Journal of Neuro-Oncology.

[5]  Jacob S. Young,et al.  Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group , 2022, Neuro-oncology.

[6]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[7]  M. Berger,et al.  Evidence-based recommendations on categories for extent of resection in diffuse glioma. , 2021, European journal of cancer.

[8]  G. Reifenberger,et al.  EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood , 2020, Nature Reviews Clinical Oncology.

[9]  S. Thust,et al.  Conventional MRI features of adult diffuse glioma molecular subtypes: a systematic review , 2020, Neuroradiology.

[10]  Sohil H. Patel,et al.  'Real world' use of a highly reliable imaging sign: 'T2-FLAIR mismatch' for identification of IDH mutant astrocytomas. , 2020, Neuro-oncology.

[11]  Sung Soo Ahn,et al.  Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma , 2020, Scientific Reports.

[12]  Jennie W. Taylor,et al.  Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. , 2020, JAMA oncology.

[13]  Sohil H. Patel,et al.  MRI and CT Identify Isocitrate Dehydrogenase (IDH)-Mutant Lower-Grade Gliomas Misclassified to 1p/19q Codeletion Status with Fluorescence in Situ Hybridization. , 2019, Radiology.

[14]  Se Hoon Kim,et al.  Radiomics MRI Phenotyping with Machine Learning to Predict the Grade of Lower-Grade Gliomas: A Study Focused on Nonenhancing Tumors , 2019, Korean journal of radiology.

[15]  M. Bydon,et al.  Impact of 1p/19q codeletion status on extent of resection in WHO grade II glioma: Insights from a national cancer registry , 2019, Clinical Neurology and Neurosurgery.

[16]  Anna Latysheva,et al.  Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach , 2019, Neuroradiology.

[17]  I. Mader,et al.  Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system , 2018, Journal of Neuro-Oncology.

[18]  D. Nam,et al.  Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  M. Vogelbaum,et al.  Supratotal resection in glioma: a systematic review , 2018, Neuro-oncology.

[20]  D. Cahill,et al.  The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study , 2018, Journal of Neuro-Oncology.

[21]  D. Louis,et al.  cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC) , 2018, Acta Neuropathologica.

[22]  M. J. van den Bent,et al.  The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis , 2017, Neuro-oncology.

[23]  S. Torp,et al.  Surgical resection versus watchful waiting in low-grade gliomas , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Chae-Yong Kim,et al.  Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  F. Ducray,et al.  Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas. , 2016, Neuro-oncology.

[26]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[27]  T. Cloughesy,et al.  NIMG-24HIGH SPATIOTEMPORAL DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI USING MULTIBAND ECHOPLANAR IMAGING (MB-EPI) , 2015 .

[28]  W. Hahn,et al.  Rapid Intraoperative Molecular Characterization of Glioma. , 2015, JAMA oncology.

[29]  F. Ducray,et al.  Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations. , 2014, Neuro-oncology.

[30]  Johan Skog,et al.  Glioblastoma microvesicles transport RNA and protein that promote tumor growth and provide diagnostic biomarkers , 2008, Nature Cell Biology.

[31]  Andrew L. A. Garton,et al.  Extent of resection and survival for oligodendroglioma: a U.S. population-based study , 2019, Journal of Neuro-Oncology.

[32]  Hugues Duffau,et al.  A better surgical resectability of WHO grade II gliomas is independent of favorable molecular markers , 2014, Journal of Neuro-Oncology.

[33]  K. Aldape,et al.  IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. , 2014, Neuro-oncology.